Neuromidin solution for injection 15 mg/ml in ampoules of 1 ml 10 pcs — Made in Latvia — Free Delivery

Indications

Diseases of the peripheral nervous system - mono- and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies;

diseases of the central nervous system: bulbar paralysis and paresis; the recovery period of organic lesions of the central nervous system, which are accompanied by movement disorders;

Application

The dose and duration of treatment are determined individually, depending on the severity of the disease.

Diseases of the peripheral nervous system: mono- and polyneuropathies of various origins: s / c or i / m 5-15 mg 1-2 times a day. The course of treatment is 10-15 days (in severe cases - up to 30 days), then the treatment is continued with the tablet form of the preparation.

Myasthenia gravis and myasthenic syndrome: s / c or i / m injected 5-30 mg 1-3 times a day with a further transition to the tablet form. The general course of treatment is 1-2 months. If necessary, the course of treatment can be repeated several times with a break between courses of 1-2 months.

Diseases of the central nervous system: bulbar paralysis and paresis - s / c or i / m 5-15 mg 1-2 times a day, the course of treatment is 10-15 days, if possible, later switch to the tablet form.

The recovery period for organic lesions of the central nervous system is 10-15 mg i / m 1-2 times a day, the course of treatment is up to 15 days, then, if possible, 1-2 times a day.

Contraindications

Hypersensitivity to ipidacrine, epilepsy, extrapyramidal disorders with hyperkinesis, angina pectoris, severe bradycardia, BA, vestibular disorders, mechanical obstruction of the intestine or urinary tract, gastric and duodenal ulcers.

Side effects

Neuromidine, like all medicines, can cause side reactions, although not everybody gets them. Neuromidin adverse reactions are associated with stimulation of m-cholinergic receptors.

Cardiac disorders: increased heart rate, bradycardia.

Disturbances from the nervous system: when used in high doses - dizziness, headache, drowsiness, general weakness, convulsions.

Respiratory system disorders: increased secretion of bronchial secretions, bronchospasm.

Digestive system disorders: increased salivation, nausea, when used in high doses - vomiting, diarrhea, jaundice, chest pain.

Lesions of the skin and subcutaneous tissue: increased sweating, when used in high doses - allergic skin reactions (rash, itching).

Reproductive system disorders: increased uterine tone.

With the development of undesirable side effects, reduce the dose or interrupt the use of the preparation for a short time (by 1-2 days). The severity of salivation and bradycardia can be reduced by blockers of M-cholinergic receptors (atropine, etc.)

Special instructions

Care should be taken when prescribing the preparation to patients with gastric and duodenal ulcers, thyrotoxicosis, diseases of the cardiovascular system, as well as patients with diseases of the respiratory system (in history in the acute stage).

Use during pregnancy and lactation. Neuromidin increases the tone of the uterus and can cause premature labor, therefore, the use of the preparation is contraindicated during pregnancy.

During lactation, the use of the preparation is contraindicated.

Children

 There is no systematic data on the use of the parenteral form of the preparation Neuromidin in children under the age of 18, therefore, do not use in children.

The ability to influence the reaction rate when driving vehicles and other mechanisms. During the period of treatment, it is necessary to refrain from driving vehicles and working with potentially dangerous mechanisms that require increased concentration of attention and speed of psychomotor reactions.

Interactions

Neuromidine enhances the sedative effect in combination with preparations that inhibit the central nervous system. the effect of the preparation and side effects are enhanced when combined with other cholinesterase inhibitors and m-cholinomimetic agents. in patients with myasthenia gravis, the risk of developing a cholinergic crisis increases if neuromidin is used concurrently with other cholinergic preparations. the risk of developing bradycardia increases if β-adrenergic receptor blockers were used before starting treatment with neuromidin. Neuromidin can be used in combination with nootropic preparations.

Alcohol increases the side effects of the preparation.

Overdose

With severe intoxication, a cholinergic crisis may develop.

Symptoms: bronchospasm, lacrimation, increased sweating, miosis, nystagmus, increased gastrointestinal motility, spontaneous defecation and urination, vomiting, jaundice, bradycardia, intracardiac conduction disturbances, arrhythmias, arterial hypotension, anxiety, anxiety, agitation, a feeling of fear coma, unintelligible speech, drowsiness and weakness.

Treatment: symptomatic therapy is used, blockers of M-cholinergic receptors are used (atropine sulfate, metacinium iodide, trihexyphenidil, etc.).

Storage conditions

In a dry, dark place at a temperature not exceeding 25 ° C.